Neonc Technologies Holdings, Inc. (NTHI) Research
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.
Market snapshot
- Symbol
- NTHI
- Price
- $5.27
- Day change
- +9.56%
- Market cap
- $105.4M
- P/E ratio
- -3.18x
- 52-week range
- 3.2-12.99
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $16.00
Recent insider activity
- Heshmatpour Amir F — P-Purchase (6000 shares) on 2025-11-24
- Heshmatpour Amir F — P-Purchase (4000 shares) on 2025-11-21
- Heshmatpour Amir F — P-Purchase (20000 shares) on 2025-11-21
- CHIANG MING-FU (ALAN) — trade (0 shares) on 2025-11-12
- CHIANG MING-FU (ALAN) — trade (0 shares) on 2025-11-12
Open Neonc Technologies Holdings, Inc. (NTHI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.